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OBJECTIVES This study was designed to test a rapid protocol of intravenous acetylcysteine for prevention
of radiocontrast-induced nephropathy (RCIN).
BACKGROUND Oral acetylcysteine (NAC) may provide better prophylaxis against RCIN than intravenous
(IV) hydration alone. Current protocols preclude prophylaxis of same-day or emergency
patients owing to the need for prolonged pretreatment.
METHODS We prospectively randomized 80 patients with stable renal dysfunction undergoing cardiac
catheterization/intervention to a rapid protocol of IV NAC (150 mg/kg in 500 ml N/saline
over 30 min immediately before contrast followed by 50 mg/kg in 500 ml N/saline over 4 h,
n  41, 67  10 years, 90% men) or IV hydration (1 ml/kg/h N/saline for 12 h pre- and
post-contrast, n  39, 71  8.8 years, 85% men).
RESULTS Radiocontrast-induced nephropathy occurred in 2 of the 41 patients in the NAC group (5%)
and in 8 of the 39 patients in the hydration group (21%; p  0.045; relative risk: 0.28; 95%
confidence interval 0.08 to 0.98). In the NAC group, mean serum creatinine fell from 1.85
 0.59 to 1.77  0.73 and 1.79  0.73 mg/dl 48 h and four days post-contrast (p  0.02
and 0.023 vs. baseline, respectively). In the hydration group, serum creatinine increased from
1.75 0.41 to 1.81 0.6 48 h and 1.80 0.50 mg/dl four days post-contrast (p 0.99 and
0.23, respectively). NAC infusion was ceased after the bolus in three patients (7%) due to
flushing, itching, or a transient rash.
CONCLUSIONS Administration of IV NAC should be considered in all patients at risk of RCIN before
contrast exposure when time constraints preclude adequate oral prophylaxis, provided the
patient is able to tolerate this degree of volume loading. (J Am Coll Cardiol 2003;41:
2114–8) © 2003 by the American College of Cardiology Foundation
Radiocontrast-induced nephropathy (RCIN) is reported to
occur in as many as 14.5% of unselected patients undergoing
coronary angiography/intervention (1), and is the third most
common cause of in-hospital acute renal failure after hypo-
tension and surgery (2). Important risk factors for RCIN
include pre-existing renal dysfunction, especially that due to
diabetic nephropathy; reduced circulating volume; the vol-
ume and type of contrast agent employed; and concomitant
administration of potentially nephrotoxic drugs (3,4). Sev-
eral agents have been proposed to provide prophylaxis
against RCIN (3). However, until recently, only saline
hydration (1 ml/kg 0.45% saline for 12 h pre- and post-
contrast exposure) has been confirmed to be effective (5).
The precise mechanisms leading to RCIN remain a
matter of debate, although the root of the problem appears
to be an injury to the renal medulla resulting from a
combination of reduced blood flow, an osmotic effect, and
direct tubular toxicity. The last of these may be a direct
result of toxic free radical release, which occurs after contrast
administration (6). Recent studies have highlighted the
potential protective effect of oral acetylcysteine (NAC), an
antioxidant, in addition to saline hydration in preventing
RCIN (7–10), although this has not been a universal finding
(11–13). The successful protocols tested to date require the
initiation of therapy on the day before contrast exposure,
precluding the treatment of same-day and emergency pa-
tients.
We therefore conducted a prospective, randomized, mul-
ticenter controlled trial to test the hypothesis that a rapid
protocol of intravenous (IV) acetylcysteine would be more
effective at inhibiting RCIN in high-risk patients undergo-
ing coronary angiography/intervention than prolonged sa-
line hydration alone.
METHODS
Patients. We studied prospectively patients undergoing
coronary angiography or intervention at three London
hospitals (London Chest Hospital, St. Bartholomew’s Hos-
pital, and the Hammersmith Hospital) between October
2001 and August 2002. All patients had a serum creatinine
(SCr) concentration 1.36 mg/dl (120 mol/l) or a creat-
inine clearance 50 ml/min calculated on the basis of SCr,
age, weight, and gender {creatinine clearance [(140 age
in years)  weight in kg]/(creatinine in mg/dl  72)} (14).
No patients with acute renal failure or end-stage renal
failure on dialysis were included. Patients who had received
a nonsteroidal anti-inflammatory agent (except aspirin 75 to
150 mg) within 24 h of the study and those with a systolic
blood pressure90 mm Hg or hemodynamically significant
valvular heart disease were excluded. Patients with signs of
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cardiac failure at the time of randomization or during the
current admission were excluded. Serum creatinine was
measured in mol/l and was converted to milligrams per
deciliter by dividing by 88.4. Serum urea was measured in
mmol/l and has been converted to blood urea nitrogen
(BUN) in mg/dl by dividing by 0.357.
Power calculations indicated a study design requiring 80
patients per group to demonstrate a 0.6 mg/dl difference in
the mean change in creatinine (similar to that seen in
previous studies [7]) with a power of 80% and a two-tailed
significance level of p 0.05. It was pre determined that the
data should be analyzed at the midpoint of the study, after
the first 80 patients had been randomized, as such numbers
had previously proved sufficient (7).
The study protocol was approved by the local ethics
committee and all patients gave written informed consent.
Study protocol. Patients were randomly assigned to receive
either acetylcysteine and IV saline or intravenous saline
alone, before and after contrast administration. Acetylcys-
teine was given IV at a dose of 150 mg/kg in 500 ml saline
(0.9%) over 30 min immediately before contrast exposure
and followed by 50 mg/kg in 500 ml saline (0.9%) over the
subsequent 4 h. In the control group, saline was given at a
rate of 1 ml/kg/h for 12 h pre- and post-procedure. Free
oral fluids were commenced immediately post-procedure in
all patients. The isotonic, nonionic contrast medium iodixa-
nol (Visipaque, Amersham Health, United Kingdom) was
used in all cases. Unless clinically contraindicated, diuretics
and angiotensin-converting enzyme inhibitors were stopped
24 h before contrast exposure and restarted only when renal
function had been shown to be stable post-procedure. No
patient received nitrates (oral or IV), theophylline, dopa-
mine, furosemide, or mannitol during the procedure. Serum
creatinine was measured immediately before angiography/
intervention and at 48 and 96 h thereafter. An acute
contrast-induced reduction in renal function was defined as
an increase in SCr concentration by 25% at either two or
four days after contrast administration (15,16).
Statistical analysis. Analysis was conducted on an
intention-to-treat basis. Categorical variables such as the
incidence of RCIN were analyzed by Fisher’s exact test.
Differences between groups were analyzed by the nonpara-
metric Wilcoxon-Mann-Whitney test. Analyses were per-
formed with GraphPad Prism software (version 3.0, Graph-
Pad Software, San Diego, California). All statistical tests
were two-sided and a p value of 0.05 was taken as
significant.
RESULTS
The trial was halted early following the interim analysis and
after randomization of the first 80 patients. A single patient
did not proceed to contrast administration owing to the
development of acute pulmonary edema following the initial
30-min infusion of acetylcysteine. At 48 and 96 h after
angiography/intervention, 76 out of 80 and 74 out of 80
patients had SCr measurements available for analysis. A
single patient from each group had no post-contrast SCr
value for analysis at either time point.
The clinical and baseline characteristics of the patients are
shown in Table 1. Mean SCr for all patients was 1.80 
0.51 mg/dl (multiply by 88.4 to convert to mol/l) (159.5
44.9 mol/l). In the control group, mean SCr increased
from 1.75  0.41 (155.0  36.6 mol/l) to 1.81  0.6
(160.1  53.0 mol/l) and 1.80  0.5 mg/dl (159.4  44.5
mol/l), 48 and 96 h after administration of the radiocon-
trast agent (p  0.99 and 0.23 respectively). In the acetyl-
cysteine group, mean SCr decreased from 1.85  0.59 to
1.77  0.73 (163.7  51.8 and 156.1  64.5 mol/l) and
1.79 0.73 mg/dl (157.9 64.4 mol/l), 48 and 96 h after
administration of the contrast agent (p  0.02 and 0.023,
respectively) (Fig. 1).
In the control group, mean BUN concentration decreased
from 29.4  12.3 mg/dl (10.5  4.4 mmol/l) (multiply by
0.357 to convert to mmol/l) to 26.1  10.6 (9.3  3.8
mmol/l) at 48 h and rose to 29.7  13.4 mg/dl (10.6  4.8
mmol/l) 96 h after administration of the radiocontrast agent
(p  0.0012 and 0.71 respectively). In the acetylcysteine
group, mean BUN decreased from 30.8  14.0 mg/dl (11.0
 5.0 mmol/l) to 28.0  13.4 and 28.9  15.1 mg/dl (10.0
 4.8 and 10.3  5.4 mmol/l), 48 and 96 h after
administration of the contrast agent (p  0.08 and 0.02,
respectively).
Acute RCIN occurred in 10 of the 80 patients (12.5%), 2
of the 41 (5%) acetylcysteine-treated patients, and 8 of the
39 fluid-treated patients (21%; p 0.045; relative risk: 0.28;
95% confidence intervals: 0.08 to 0.98) (Fig. 2, Table 2). No
Abbreviations and Acronyms
BUN  blood urea nitrogen
IV  intravenous
NAC  N-acetylcysteine
RCIN  radiocontrast-induced nephropathy
SCr  serum creatinine








Age (yrs) 67.4  10.3 70.9  8.8
Gender (M/F) 37/4 33/6
Weight (kg) 79.2  15.5 81.2  16.0
Serum creatinine (mg/dl) 1.85  0.59 1.75  0.41
Calculated creatinine clearance 45  13 44  18
Diabetes mellitus, no. (%) 17 (41) 17 (44)
Calcium channel blockers, no. (%) 17 (41) 14 (36)
Diuretic therapy, no. (%) 19 (46) 26 (67)
Angiotensin-converting enzyme
inhibitor, no. (%)
25 (61) 23 (59)
Angiogram/angioplasty 20/20 21/18
Volume of radiocontrast (ml) 238  155 222  162
Plus-minus values are means SD. There were no significant differences between the
groups (p  0.05 for all comparisons).
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patient required renal replacement therapy. Five of the 10
patients with an acute contrast agent-induced reduction in
renal function had diabetes mellitus. The mean contrast
dose in patients developing an acute contrast agent-induced
reduction in renal function was 253 ml (range 120 to 700
ml).
Adverse events occurred in 10 of the 80 patients (12.5%).
Pulmonary edema occurred in two patients from each group
(4 out of 80 patients, 5%). In one patient left ventricular
failure occurred before angiography; the acetylcysteine in-
fusion was stopped after the bolus and the procedure
postponed. In three patients, this complication occurred
after angiography alone (mean contrast dose 128  21 ml)
and infusions were halted early. Itching, flushing, or tran-
sitory rash was reported in six patients following the 30-min
infusion of acetylcysteine (14.6%). In all six patients, symp-
toms resolved spontaneously with cessation of the infusion.
Three patients declined the 4-h infusion owing to this
complication. In the other three, the 4-h acetylcysteine
infusion was commenced when the suspected side effect had
resolved without further incident. A single patient received
hydrocortisone and continued the acetylcysteine infusion.
No patients received antihistamines.
DISCUSSION
The major finding of this study is that treatment of patients
with a rapid protocol of IV acetylcysteine and 0.9% saline
started immediately before coronary angiography/
intervention reduced the incidence of radiocontrast-induced
deterioration in renal function compared with a standard
12-h protocol of saline hydration alone. In addition, the
absolute change in SCr concentration was less in the
acetylcysteine-treated patients than in the hydration-alone
group. This was due in part to a significant fall in SCr
concentration in the acetylcysteine group.
Previous studies have demonstrated the efficacy of oral
acetylcysteine in preventing RCIN in the setting of
contrast-assisted computerized tomography (low volumes of
IV contrast) (7,10) and following coronary angiography (8)
or intervention (9). In all three studies, acetylcysteine was
given for 12 to 24 h before contrast exposure. Our findings
show that a similar degree of protection is afforded to
patients undergoing either angiography or percutaneous
coronary intervention by a rapid protocol of IV acetylcys-
teine administered immediately before the procedure.
The reduction in the incidence of RCIN we have ob-
served is similar to those of previous studies that have
reported an incidence of RCIN of between 2% and 8%
(7–10) in patients treated with oral acetylcysteine. A similar
incidence of RCIN was also seen between the control
groups pretreated for 12 h with IV saline (21% to 25%) (7,9)
though the rate was higher when saline hydration was less
prolonged (8).
The fall in SCr concentration in response to acetylcys-
teine seen in this study is also consistent with previous
reports (7–10). The mechanism of this decline remains
unknown but is likely to be a result of changes in glomerular
filtration rate. The rise in SCr concentration in the control
group reflects, in all probability, a reduction in glomerular
filtration rate. The apparently discrepant fall in serum urea
likely results from reduced renal tubular urea reabsorption
consequent upon hydration, together with the volume
expanding effect of hydration itself.
The results of studies of acetylcysteine have varied in their
Table 2. Baseline Serum Creatinine, Change in Creatinine at 48
and 96 h and Incidence of Acute Reduction in Renal Function











Baseline 1.85  0.59 1.75  0.41 0.59
Change at 48 h 0.08  0.34 0.05  0.31 0.044*
Change at 96 h 0.08  0.32 0.09  0.29 0.008*
Incidence of acute reductions
in renal function, no. (%)
2 (4.9) 8 (20.5) 0.045†
Plus-minus values are means  SD. Mean serum creatinine concentration fell
significantly in the acetylcysteine treated group and rose nonsignificantly in the fluid
treated group. *The Wilcoxon-Mann-Whitney U test was used for the comparison
between groups. †Fisher exact test was used for the comparison between groups.
Figure 1. Changes in serum creatinine before and after radiocontrast
exposure White bars  acetylcysteine; striped bars  control.
Figure 2. Incidence of post-cardiac catheterization/intervention radiocontrast-
induced nephropathy (RCIN). p  0.045; relative risk 0.28.
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findings with no benefit reported from three randomized
trials of oral acetylcysteine (11–13). Briguori et al. (11)
failed to reproduce the original findings of Tepel et al. (7) in
patients undergoing coronary angiography/intervention pre-
treated with drug. This discrepancy is not easy to account
for. However, the incidence of RCIN in the control group
(11%) was less than that of other studies, perhaps owing to
the relatively well-preserved renal function of patients in
this study group as a whole. Serum creatinine was measured
only at 48 h, and a number of patients with late-developing
RCIN may have been missed. Serum creatinine was mea-
sured up to 96 h in the current study, as RCIN can develop
late. Previous evidence suggests that in approximately 90%
of patients with RCIN the SCr will have risen by 72 h (3).
This criticism may also apply to the studies of Durham et al.
(12) and Allaqaband et al. (13). In the former study the
protocol also differed in the timing of drug administration.
Acetylcysteine was initiated only 1 h pre-contrast exposure
although, as the authors point out, oral dosing produces
peak drug levels at 1 h, and the results of our study would
indicate that prolonged pre-exposure to acetylcysteine is not
necessary.
The dose of IV acetylcysteine chosen for the current study
was derived from the standard regimen for the treatment of
paracetamol overdose and at this dose 14.5% of patients
suffered flushing, itching or rash. These “anaphylactoid” or
“hypersensitivity-like” side effects are, however, well recog-
nized and easily managed. The data sheet recommendations
of halting the infusion of acetylcysteine and reintroducing
the drug at a reduced infusion rate were followed in this
study without further complication. No incidence of
acetylcysteine-associated death has been reported to date
(company information). The incidence of treatment-
induced pulmonary edema, though equal in both groups,
was higher than might be expected. This may reflect the
patient population studied, many of whom likely had
impaired left ventricular function, judging by the extensive
use of diuretics and angiotensin-converting enzyme inhibi-
tors. In practice, excluding patients with significant echo-
cardiographic impairment of left ventricular function could
reduce the risk of pulmonary edema. This could be per-
formed immediately before the contrast exposure and in
place of left ventriculography with its attendant contrast
load.
The reduced nephrotoxicity of low-osmolality contrast
media has been demonstrated both in large studies and by
meta-analysis (17,18). A nonionic iso-osmolar medium,
iodixanol, was used in this study, as it had been suggested to
be even less nephrotoxic on the basis of a reduction in renal
tubular enzyme excretion following contrast exposure. Io-
dixanol had also been reported to reduce RCIN (as defined
as a 10% rise in SCr) compared with iohexol in a high-risk
group undergoing angiography (19). Evidence available
since completion of the study has proven to be consistent
with this view (20).
Study limitations. Limitations of our multicenter study
include the small sample size. Additionally, the statistical
difference between the groups, as in other similar studies,
does not necessarily indicate that acetylcysteine will prevent
clinically important RCIN, or reduce the incidence of
RCIN requiring renal replacement therapy or the mortality
from this complication.
An inevitable consequence of aiming to compare a
same-day protocol with one requiring pre-admission of the
patient was that the rate of saline infusion differed between
the two groups. Our protocol dictated that patients in the
acetylcysteine group receive 1 liter over 4 h, those in the
control group receiving the more standard liter over 12 h.
We think it more likely that the acetylcysteine was respon-
sible for our findings than was the rate of fluid administra-
tion.
The influence of different renal pathologies on the effec-
tiveness of acetylcysteine in preventing RCIN was not
explored in this study, nor was the effect of acetylcysteine on
the long-term outcomes of patients with abnormal renal
function exposed to radiocontrast. The dose of acetylcys-
teine chosen was, it may be argued, larger than necessary to
prevent RCIN. It may be that a substantially lower intra-
venous dose would be equally effective and might result in a
reduced risk of side effects. This question merits further
study.
Conclusions. The IV infusion of acetylcysteine (150
mg/kg in 500 ml 0.9% saline) immediately before coronary
angiography/intervention and followed by a 4-h infusion of
acetylcysteine (50 mg/kg in 500 ml 0.9% saline) is an
effective means of preventing transient renal dysfunction
due to the non-ionic, iso-osmolar radiocontrast medium
iodixanol. Administration of intravenous NAC should be
considered in all patients at risk of RCIN before contrast
exposure when time constraints preclude adequate oral
prophylaxis. Care must be taken in the treatment of patients
with impaired left ventricular function.
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